Last quarter (Q2 2022), Oxford BioMedica's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, Oxford BioMedica's net income was £―. See Oxford BioMedica’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	£ 139.99M	£ 142.80M	£ 87.73M	£ 64.06M	£ 66.78M
Cost of Revenue	-	£ 70.81M	£ 60.16M	£ 41.66M	£ 43.10M	£ 34.50M
Gross Profit	-	£ 69.18M	£ 82.64M	£ 46.07M	£ 20.96M	£ 32.27M
Operating Expense	-	£ 123.05M	£ 61.71M	£ 50.94M	£ 33.54M	£ 24.34M
Operating Income	-	£ -53.87M	£ 20.93M	£ -4.86M	£ -12.58M	£ 7.93M
Net Non Operating Interest Income Expense	-	£ -7.78M	£ 888.00K	£ -878.00K	£ -5.45M	£ -6.16M
Other Income Expense	-	£ -23.64M	-	-	-	-
Pretax Income	-	£ -45.98M	£ 19.88M	£ -6.57M	£ -20.89M	£ 5.01M
Tax Provision	-	£ -817.00K	£ 869.00K	£ -327.00K	£ -4.82M	£ -2.53M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -39.16M	£ 19.01M	£ -6.25M	£ -16.07M	£ 7.54M
Basic EPS	-	£ -0.41	£ 0.23	£ -0.08	£ -0.22	£ 0.12
Diluted EPS	-	£ -0.41	£ 0.22	£ -0.08	£ -0.22	£ 0.11
Basic Average Shares	-	£ 94.83M	£ 83.48M	£ 79.94M	£ 72.71M	£ 65.19M
Diluted Average Shares	-	£ 94.83M	£ 83.48M	£ 79.94M	£ 72.71M	£ 69.24M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	£ 173.00K	£ 104.00K	£ 30.00K
Total Expenses	-	£ 193.85M	£ -121.86M	£ 92.59M	£ 76.64M	£ 58.85M
Net Income From Continuing And Discontinued Operation	-	£ -39.16M	£ 19.01M	£ -6.25M	£ -16.07M	£ 7.54M
Normalized Income	-	£ -46.79M	£ 16.10M	£ -5.46M	£ -14.62M	£ 2.69M
Interest Expense	-	-	-	£ 912.00K	£ 5.56M	£ 6.23M
EBIT	-	£ -37.22M	£ 20.77M	£ -5.66M	£ -15.33M	£ 11.24M
EBITDA	-	£ -10.28M	£ 20.77M	£ 4.18M	£ -9.54M	£ 15.60M

Currency in GBP

Oxford BioMedica Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing